{"analyses":[{"ciLowerLimit":"-2.4","ciPctValue":"95","ciUpperLimit":"30.1","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0900","pValueComment":"Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites).\n\nStatistically significant at pre-specified alpha of 20%","paramType":"Difference in Percentage of Participants","paramValue":"13.9","statisticalMethod":"Cochran-Mantel-Haenszel"},{"ciLowerLimit":"3.2","ciNumSides":"TWO_SIDED","ciPctValue":"80","ciUpperLimit":"24.5","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.0900","pValueComment":"Stratified by race (Afro Caribbean/African American vs. Others) and region (US vs. non-US sites).\n\nStatistically significant at pre-specified alpha of 20%","paramType":"Difference in Percentage of Participants","paramValue":"13.9","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"63"},{"groupId":"OG001","value":"62"}],"units":"Participants"}],"description":"mCRR1 has got two components only, i.e. serum Creatinine and urinary protein to creatinine ratio. mCRR1 is defined by attainment of normalization of serum creatinine as evidenced by 1.) serum creatinine ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine is above the ULN or serum creatinine ≤15% above baseline and ≤ the ULN range of central laboratory values if baseline (Day 1) serum creatinine ≤ the ULN range of central laboratory values and 2.) Urinary protein to creatinine ratio \\<0.5.","groups":[{"description":"Participants received obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 grams per day (g/day) (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"OG000","title":"OBINUTUZUMAB 1000MG and MMF"},{"description":"Participants received placebo matching to obinutuzumab IV infusion on Days 1, 15, 168, and 182 along with MMF/MPA at a starting dose of 1500 mg/day (or equivalent) administered orally in 2 or 3 divided doses. MMF/MPA dose was up titrated to a target dose of 2.0 - 2.5 g/day (or equivalent). Investigators, at their discretion, could use MPA as a substitute for MMF, with a 360 mg dose being equivalent to a 500 mg dose of MMF. During screening or at randomization, if clinically indicated, participants could receive 1000 mg methylprednisolone IV once daily for up to 3 days to treat underlying LN clinical activity. Participants received 0.5 mg/kg oral prednisone, tapering this prednisone dose, per protocol, starting on Day 16 and reducing the prednisone dosage to 7.5 mg/day by Week 12.","id":"OG001","title":"PLACEBO and MMF"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Modified intent-to-treat population will include all randomized participants who have received any amount of study drug. Participants who received an incorrect therapy were reported under the treatment arm to which they were randomized.","reportingStatus":"POSTED","timeFrame":"Week 52","title":"Percentage of Participants Who Achieve Protocol Defined Modified CRR (mCRR1) at Week 52","type":"SECONDARY","unitOfMeasure":"Participants"}